Driving Innovation:
V||V Healthcare's Long-Acting Pipeline
Assets in development target multiple stages of the
HIV life cycle with expanded dosing options
Binding & Fusion
X
Binding & Fusion1
Class: Broadly Neutralising Antibodies (bNAbs)
- VH3810109 (N6LS) – Phase IIb
Mechanism of Action video - VH4527079 (bi-specific)2 – Phase I
- Bibliography
Nuclear Entry & Uncoating
X
Nuclear Entry & Uncoating1
Class: Capsid Inhibitors
Mechanism of Action Video- VH4011499 – Phase IIa
- Bibliography
Integration
X
Integration1
Class: Integrase Inhibitors
- CAB-ULA (Tx/PrEP) – Phase Ia/IIb
- VH45241843 – Phase IIa
Barrier to Resistance Video - VH4367310 – Phase Ia4
- Bibliography
Assembly & Budding
X
Assembly & Budding1
Class: Capsid Inhibitors
Mechanism of Action Video- VH4011499 - Phase IIa
- Bibliography
1Binding and Fusion1
Class: Broadly Neutralising Antibodies (bNAbs)
- VH3810109(N6LS) – Phase IIb
Mechanism of Action video - VH4527079 (bi-specific)2 – Phase I
- Bibliography
2Nuclear Entry & Uncoating1
3Integration1
Class: Integrase Inhibitors
- CAB-ULA (Tx/PrEP) – Phase Ia/IIb
- VH45241843 – Phase IIa
Barrier to Resistance Video - VH4367310 – Phase Ia4
- Bibliography
4Assembly and Budding1
- GSK. ViiV Healthcare meet the management: Getting ahead of HIV together – 2023. Available at: https://www.gsk.com. Accessed April 2025
- NCT06652958. Available at: https://clinicaltrials.gov. Accessed April 2025.
- NCT06214052. Available at: https://clinicaltrials.gov. Accessed April 2025
- Baker M, et al